NCT04511936 (i-SIGHT) is a NA clinical trial of i-Lumen AMD in Dry Age-related Macular Degeneration, sponsored by i-Lumen Scientific, Inc..

Who is sponsoring NCT04511936?

NCT04511936 is sponsored by i-Lumen Scientific, Inc..

What drugs are being tested in NCT04511936?

Interventions in NCT04511936: i-Lumen AMD, i-Lumen AMD Sham.

What condition does NCT04511936 study?

NCT04511936 studies Dry Age-related Macular Degeneration.

Is NCT04511936 still recruiting?

NCT04511936 is currently withdrawn. Last updated 8 April 2021.

Last reviewed 2021-04-08 · How we verify

NCT04511936: i-SIGHT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Microcurrent Stimulation for Dry Age-related Macular Degeneration

Withdrawn NA Last updated 8 April 2021

What this trial tests

NA trial testing i-Lumen AMD in Dry Age-related Macular Degeneration. Withdrawn.

Timeline

1 March 2021

Primary endpoint
31 January 2022

31 January 2023

Quick facts

Lead sponsor	i-Lumen Scientific, Inc.
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Start date	1 March 2021
Primary completion	31 January 2022
Estimated completion	31 January 2023

Drugs / interventions tested

i-Lumen AMD
i-Lumen AMD Sham

Conditions studied

Dry Age-related Macular Degeneration — all drugs for Dry Age-related Macular Degeneration →

Sponsor

i-Lumen Scientific, Inc.

Who can join

50 and older, any sex, with Dry Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate the safety and efficacy of microcurrent stimulation therapy for patients with dry age-related macular degeneration.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of i-Lumen AMD

Trials testing the same drug.

NCT06662162 — Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration · NA · recruiting

Other recruiting trials for Dry Age-related Macular Degeneration

Currently open trials in the same condition.

NCT06536062 — Age-related Macular Degeneration of Atrophic Type Treated With Umbilical Cord Blood Enriched With Platelet Plasma. · NA · recruiting
NCT06229665 — Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB) · Phase 2, PHASE3 · active not recruiting
NCT05797896 — Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study · active not recruiting
NCT05706896 — Atrophic Age-related Macular Degeneration Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Pla · NA · recruiting
NCT04627428 — Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular · Phase 1, PHASE2 · recruiting

Other i-Lumen Scientific, Inc. trials

Trials by the same sponsor.

NCT05447650 — Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT) · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04511936 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by i-Lumen Scientific, Inc.
Last refreshed: 8 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04511936.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing